Drug Trial Radar · NCT07898800
Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 29, 2026
Primary completion
Mar 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Desentum OyIndustry
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of DM-101-PX compared to placebo in birch pollen allergic adults. As an secondary objectives, the trial will also assess the number of participants receiving the maximum intended DM-101PX dose and to assess the effect of treatment with DM-101PX compared with placebo on blood allergy biomarkers. Expanded access to the study treatment is not available.
Conditions
- Birch Pollen Allergy
Interventions
DM-101PXBiological
Subcutaneous injection of DM-101PX
PlaceboBiological
Placebo to match subcutaneous injection of DM-101PX
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Emergent Adverse EventsTime frame: From the first dose to until 3 months from the last dose
- Adverse Events of Special InterestTime frame: From the first dose to until 3 months from the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM
Hanover, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.